Seed Funding

'Is the worst behind us?' Financial expert talks biotech funding 'Is the worst behind us?' Financial expert talks biotech funding

Biotech venture funding has recovered during the first two quarters of 2024 but IPO activity remains sluggish, according to Brian Scanlan, partner at Edgewater Capital.

byBrian Scanlan, Dan Stanton

Oct 21, 2024

|

1 Min Read

The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B

byMillie Nelson

Oct 17, 2024

1 Min Read

Overhead view of business people working and funding

$325 million Series C funding in its Arsenal (Biosciences)$325 million Series C funding in its Arsenal (Biosciences)

byMillie Nelson

Sep 25, 2024

1 Min Read

People making business deals

Prometheus and Merck: Under the bonnet of the largest pre-Phase III M&A deal Under the bonnet of the largest pre-Phase III M&A deal

byMillie Nelson

Sep 25, 2024

1 Min Read

GSK, Novartis, Calliditas among winners at LSX Awards GSK, Novartis, Calliditas among winners at LSX Awards

byMillie Nelson

Nov 16, 2023

1 Min Read

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.